Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate

NEXT STORY
Quipt Home Medical Announces Record Preliminary Fourth Quarter 2021 Results and Provides a Business Update
PREV STORY
Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Pfizer’s TALZENNA® (talazoparib)

SALT LAKE CITY, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), ...

author_avatar
NASDAQ Market News

Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency

author_avatar
NASDAQ Market News

Updated Recommendations from the World Health Organization Further Support Use of Ebola Vaccine Regimen from Johnson & Johnson and Bavarian Nordic

author_avatar
NASDAQ Market News